<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01363999</url>
  </required_header>
  <id_info>
    <org_study_id>WP25642</org_study_id>
    <nct_id>NCT01363999</nct_id>
  </id_info>
  <brief_title>A Formulation Screening Study of Dalcetrapib and Atorvastatin in Healthy Volunteers</brief_title>
  <official_title>A Single-center, Randomized, Open-label, Four Treatments, Four Periods, Four Sequence, Four-way Crossover Study to Explore the Pharmacokinetic Performance of Dalcetrapib and Atorvastatin Fixed Dose Combination Prototype Formulations in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      A single-center, crossover study to evaluate the pharmacokinetics of dalcetrapib and
      atorvastatin from prototype fixed dose combination formulations in healthy volunteers.
      Volunteers will receive a single dose of dalcetrapib with atorvastatin in each of four
      treatment periods.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Concentration of Dalcetrapib Active Form</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentration of Atorvastatin</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Atorvastatin Metabolites</measure>
    <time_frame>3 days</time_frame>
    <description>Measuring the amount of byproducts of the metabolization of Atorvastatin in the blood plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of Serious Adverse Events</measure>
    <time_frame>9 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RO5317116/F01 bilayer tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RO5317116/F03 bilayer tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RO5317116/F04 active-coated tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RO4607381/F49 tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
    <description>single dose of atorvastatin on day 1</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dalcetrapib</intervention_name>
    <description>single dose of dalcetrapib on day 1</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers, 18 to 55 years of age, inclusive

        Exclusion Criteria:

          -  Any concomitant disease or ongoing condition that in the investigator's opinion could
             interfere with the study or could pose an unacceptable risk to the patient

          -  Clinically significant abnormal laboratory values
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>May 31, 2011</study_first_submitted>
  <study_first_submitted_qc>June 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2011</study_first_posted>
  <results_first_submitted>July 17, 2019</results_first_submitted>
  <results_first_submitted_qc>December 13, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 17, 2019</results_first_posted>
  <last_update_submitted>December 13, 2019</last_update_submitted>
  <last_update_submitted_qc>December 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Dalcetrapib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Total Study</title>
          <description>All AE and Demographic Data is listed for the Total Study Population</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>A: RO5317116/F01 Bilayer Tablet</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>B: RO5317116/F03 Bilayer Tablet</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>C: RO5317116/ F04 Active-coated Tablet</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>D: RO4607381/ F49 Tablet</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Total Study</title>
          <description>All AE and Demographic Data is listed for the Total Study Population</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.1" spread="9.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasma Concentration of Dalcetrapib Active Form</title>
        <time_frame>3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A, RO5317116/F01 Bilayer Tablet</title>
            <description>RO5317116/F01 bilayer tablet
atorvastatin: single dose of atorvastatin on day 1
dalcetrapib: single dose of dalcetrapib on day 1</description>
          </group>
          <group group_id="O2">
            <title>B, RO5317116/F03 Bilayer Tablet</title>
            <description>RO5317116/F03 bilayer tablet
atorvastatin: single dose of atorvastatin on day 1
dalcetrapib: single dose of dalcetrapib on day 1</description>
          </group>
          <group group_id="O3">
            <title>C, RO5317116/F04 Active-coated Tablet</title>
            <description>RO5317116/F04 active-coated tablet
atorvastatin: single dose of atorvastatin on day 1
dalcetrapib: single dose of dalcetrapib on day 1</description>
          </group>
          <group group_id="O4">
            <title>D, RO4607381/F49 Tablet</title>
            <description>RO4607381/F49 tablet
atorvastatin: single dose of atorvastatin on day 1
dalcetrapib: single dose of dalcetrapib on day 1</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of Dalcetrapib Active Form</title>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="285" spread="68.2"/>
                    <measurement group_id="O2" value="272" spread="61.9"/>
                    <measurement group_id="O3" value="294" spread="42"/>
                    <measurement group_id="O4" value="231" spread="55.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Concentration of Atorvastatin</title>
        <time_frame>3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A, RO5317116/F01 Bilayer Tablet</title>
            <description>RO5317116/F01 bilayer tablet
atorvastatin: single dose of atorvastatin on day 1
dalcetrapib: single dose of dalcetrapib on day 1</description>
          </group>
          <group group_id="O2">
            <title>B, RO5317116/F03 Bilayer Tablet</title>
            <description>RO5317116/F03 bilayer tablet
atorvastatin: single dose of atorvastatin on day 1
dalcetrapib: single dose of dalcetrapib on day 1</description>
          </group>
          <group group_id="O3">
            <title>C, RO5317116/F04 Active-coated Tablet</title>
            <description>RO5317116/F04 active-coated tablet
atorvastatin: single dose of atorvastatin on day 1
dalcetrapib: single dose of dalcetrapib on day 1</description>
          </group>
          <group group_id="O4">
            <title>D, RO4607381/F49 Tablet</title>
            <description>RO4607381/F49 tablet
atorvastatin: single dose of atorvastatin on day 1
dalcetrapib: single dose of dalcetrapib on day 1</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of Atorvastatin</title>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.56" spread="46.5"/>
                    <measurement group_id="O2" value="3.55" spread="50.8"/>
                    <measurement group_id="O3" value="4.26" spread="60.8"/>
                    <measurement group_id="O4" value="3.86" spread="61.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of Atorvastatin Metabolites</title>
        <description>Measuring the amount of byproducts of the metabolization of Atorvastatin in the blood plasma.</description>
        <time_frame>3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A, RO5317116/F01 Bilayer Tablet</title>
            <description>RO5317116/F01 bilayer tablet
atorvastatin: single dose of atorvastatin on day 1
dalcetrapib: single dose of dalcetrapib on day 1</description>
          </group>
          <group group_id="O2">
            <title>B, RO5317116/F03 Bilayer Tablet</title>
            <description>RO5317116/F03 bilayer tablet
atorvastatin: single dose of atorvastatin on day 1
dalcetrapib: single dose of dalcetrapib on day 1</description>
          </group>
          <group group_id="O3">
            <title>C, RO5317116/F04 Active-coated Tablet</title>
            <description>RO5317116/F04 active-coated tablet
atorvastatin: single dose of atorvastatin on day 1
dalcetrapib: single dose of dalcetrapib on day 1</description>
          </group>
          <group group_id="O4">
            <title>D, RO4607381/F49 Tablet</title>
            <description>RO4607381/F49 tablet
atorvastatin: single dose of atorvastatin on day 1
dalcetrapib: single dose of dalcetrapib on day 1</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of Atorvastatin Metabolites</title>
          <description>Measuring the amount of byproducts of the metabolization of Atorvastatin in the blood plasma.</description>
          <units>ng/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" spread="37.2"/>
                    <measurement group_id="O2" value="2.51" spread="50.7"/>
                    <measurement group_id="O3" value="2.95" spread="46.9"/>
                    <measurement group_id="O4" value="2.77" spread="51.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety: Incidence of Serious Adverse Events</title>
        <time_frame>9 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A, RO5317116/F01 Bilayer Tablet</title>
            <description>RO5317116/F01 bilayer tablet
atorvastatin: single dose of atorvastatin on day 1
dalcetrapib: single dose of dalcetrapib on day 1</description>
          </group>
          <group group_id="O2">
            <title>B, RO5317116/F03 Bilayer Tablet</title>
            <description>RO5317116/F03 bilayer tablet
atorvastatin: single dose of atorvastatin on day 1
dalcetrapib: single dose of dalcetrapib on day 1</description>
          </group>
          <group group_id="O3">
            <title>C, RO5317116/F04 Active-coated Tablet</title>
            <description>RO5317116/F04 active-coated tablet
atorvastatin: single dose of atorvastatin on day 1
dalcetrapib: single dose of dalcetrapib on day 1</description>
          </group>
          <group group_id="O4">
            <title>D, RO4607381/F49 Tablet</title>
            <description>RO4607381/F49 tablet
atorvastatin: single dose of atorvastatin on day 1
dalcetrapib: single dose of dalcetrapib on day 1</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Incidence of Serious Adverse Events</title>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Total Study</title>
          <description>All AE and Demographic Data is listed for the Total Study Population. Data was not collected by arm since all interventions contained the same formulation.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal Allergy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Appendectomy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia Repair</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ryan Black</name_or_title>
      <organization>DalCor Pharmaceuticals</organization>
      <email>rblack@dalcorpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

